Metastatic disease represents a serious and often fatal development in patients with solid tumours, including women with breast cancer and dogs with mammary tumours. Therefore, preventing and treating metastatic disease has remained a priority in cancer research. Desmopressin, a synthetic derivative of vasopressin, traditionally used to treat patients with bleeding disorders, has been proposed as a potential anti‐metastatic agent due to its effect on haemostasis as well as multiple other anti‐proliferative and anti‐angiogenic mechanisms. The purpose of this study was to retest desmopressin in dogs with mammary carcinomas. A prospective randomized study was performed. Twenty‐four dogs with mammary carcinomas were enrolled; 12 dogs received perioperative desmopressin and 12 received placebo. All dogs underwent standard pre‐surgical staging followed by complete resection of all tumours. Intact dogs were spayed. All tumours were graded and classified according to the published guidelines. Follow‐up was performed every 4 months the first year and every 6 months thereafter. Necropsies were requested on all dogs. There was no difference in time to primary metastasis or survival between desmopressin treated dogs and the placebo arm (P = .43 and .73, respectively). The distribution of negative prognostic factors, including tumour grade, stage, and high vs low bioscore (refined flexible bioscoring) category between arms was not statistically different, even though more dogs in the placebo arm had grade 3 tumours and high bioscores. Based on the results of this study, perioperative desmopressin does not prevent metastasis in dogs with mammary carcinomas.

中文翻译：

---

去氨加压素治疗犬乳腺癌的前瞻性随机试验。

转移性疾病代表实体瘤患者的严重且通常是致命的发展，包括患有乳腺癌的女性和患有乳腺肿瘤的狗。因此，预防和治疗转移性疾病一直是癌症研究的重点。去氨加压素是一种血管加压素的合成衍生物，传统上用于治疗出血性疾病患者，由于其对止血的作用以及多种其他抗增殖和抗血管生成机制，已被提议作为一种潜在的抗转移药物。本研究的目的是在患有乳腺癌的狗中重新测试去氨加压素。进行了一项前瞻性随机研究。招募了 24 只患有乳腺癌的狗；12 只狗在围手术期接受去氨加压素治疗，12 只狗接受安慰剂治疗。所有的狗都接受了标准的术前分期，然后完全切除了所有肿瘤。完好的狗被绝育。根据已发表的指南对所有肿瘤进行分级和分类。第一年每 4 个月进行一次随访，此后每 6 个月进行一次随访。要求对所有狗进行尸检。去氨加压素治疗的狗和安慰剂组的原发性转移或存活时间没有差异（P = .43 和 .73，分别）。尽管安慰剂组中更多的狗患有 3 级肿瘤和高生物评分，但各组之间负面预后因素的分布，包括肿瘤分级、分期和高低生物评分（精细灵活的生物评分）类别没有统计学差异。根据这项研究的结果，围手术期去氨加压素并不能预防患有乳腺癌的犬的转移。